Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-23-007490
Filing Date
2023-05-01
Accepted
2023-05-01 16:17:41
Documents
17

Document Format Files

Seq Description Document Type Size
1 DEF 14A tgtx-20230614xdef14a.htm   iXBRL DEF 14A 898402
2 GRAPHIC tgtx-20230614xdef14a_a001.jpg GRAPHIC 7956
3 GRAPHIC tgtx-20230614xdef14a_bg001.jpg GRAPHIC 123903
4 GRAPHIC tgtx-20230614xdef14a_bg002.jpg GRAPHIC 102093
  Complete submission text file 0001558370-23-007490.txt   2140596

Data Files

Seq Description Document Type Size
5 EX-101.SCH tgtx-20230614.xsd EX-101.SCH 5865
6 EX-101.DEF tgtx-20230614_def.xml EX-101.DEF 7678
7 EX-101.LAB tgtx-20230614_lab.xml EX-101.LAB 14001
8 EX-101.PRE tgtx-20230614_pre.xml EX-101.PRE 6957
11 EXTRACTED XBRL INSTANCE DOCUMENT tgtx-20230614xdef14a_htm.xml XML 196962
Mailing Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 (212) 554-4484
TG THERAPEUTICS, INC. (Filer) CIK: 0001001316 (see all company filings)

EIN.: 363898269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-32639 | Film No.: 23873928
SIC: 2834 Pharmaceutical Preparations